[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

By N. Mottet, J. Bellmunt, Michel Bolla, Steven Joniau, M. Mason, V. Matveev, Hans-Peter Schmid, T. Kwast, Thomas Wiegel, F. Zattoni and 1 more. Actas Urológicas Españolas, 2011

883 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2604e28e472e12ec37a9c052b3901ed5c664b16f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Michel Bolla
2. N. Mottet
3. J. Bellmunt
4. M. Hallek
5. Steven Joniau
6. C. Crews
7. Thomas Wiegel

In Pulmonary and Respiratory Medicine

1. Michel Bolla
2. N. Mottet
3. J. Bellmunt
4. M. Hallek
5. Steven Joniau
6. Thomas Wiegel

Citations in the corpus

• Prostate Cancer (2018, methodology): “A recent policy statement from the American Urologic Association seeks to address the use of MRI for diagnosis and management of prostate cancer [18].”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, background): “A prior summary of the European Association of Urology (EAU) Guidelines on prostate cancer (PCa) was published in 2013 [1].”
• Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy (2012, background): “On the basis of this concept of linearity, especially in the relationship between T and prostate cancer, androgen deprivation therapy (ADT) has always been confirmed as a standard treatment for metastatic prostate cancer (25), with the specific purpose of completely breaking down circulating T level”
• PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer (2016, background): “However, the disease eventually progresses to a more aggressive form known as castration-resistant prostate cancer (CRPC), which presents clinically as an increase in serum prostate-specific antigen (PSA) while circulating testosterone remains at castration levels (4).”
• Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. (2018, neutral): “However, androgen receptor signaling plays a central role in the biology of prostate cancer, T administration promotes the growth of metastatic prostate cancer, and androgen ablation can provide benefits for aggressive prostate cancer (113, 114).”
• Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy (2015, background): “The detection rate of 58% in patients with a PSA level , 0.5 ng/mL has, in particular, a clinical impact because urological guidelines (e.g., European Association of Urology (34)) define a PSA value of 0.5 ng/mL as the upper limit for salvage radiation therapy.”